CYP3A5 and graft versus host disease: Yamashita et al. [21] reported that recipients with the CYP3A5*1 allele (n = 11) exhibited a significantly higher cumulative rate of grade 3–4 acute GVHD than those with CYP3A5*3/*3 (n = 13) within 100 days after HSCT.